Glucose–Lipid Metabolic Dysfunction and Skeletal Fragility: Bone Quality, Repair Biology, and Targeted Endocrine/Metabolic Interventions

Glucose–lipid metabolic dysfunction, increasingly prevalent with the worldwide rise in obesity, type 2 diabetes, and aging, has emerged as a critical factor affecting skeletal health. Recent epidemiological and mechanistic studies highlight strong associations between metabolic dysregulation and both bone quality deterioration and heightened fracture risk. While traditional anti-osteoporotic treatments predominantly target bone remodeling pathways, they often overlook the metabolic disturbances that underlie and exacerbate skeletal fragility. Despite advances, a comprehensive understanding of the intersection between whole-body metabolic health and bone biology (particularly concerning repair mechanisms, the impact of energy substrates, and the effects of endocrine disturbances) remains incomplete. Existing research has begun to elucidate mediators such as adipokines, insulin resistance, and altered bone marrow microenvironment, but large-scale translational and clinical studies are still needed to clarify these relationships and drive better preventive and therapeutic options.This Research Topic aims to advance and integrate knowledge on how glucose–lipid metabolic dysfunction drives impairments in bone quality and repair, and to foster the development of targeted interventions that can jointly address metabolic and skeletal health. Key objectives include elucidating the mechanistic links between metabolic dysregulation (as seen in obesity and diabetes) and skeletal fragility, evaluating innovative pharmacological and non-pharmacological therapies, and identifying novel biomarkers and tools for risk stratification. By encouraging multidisciplinary investigation, this collection pursues new translational insights and the repurposing of metabolic drugs for bone health, ultimately aiming to lay the groundwork for more effective, integrated strategies to reduce fracture risk in at-risk populations.The scope of this Research Topic encompasses metabolic-related skeletal disorders, emphasizing interdisciplinary perspectives on pathogenesis, diagnostics, and intervention, but excludes unrelated genetic, infectious, and malignant bone diseases. To gather further insights into these boundaries, we welcome articles addressing, but not limited to, the following themes:o Mechanistic and population-based studies linking metabolic dysfunction (obesity, diabetes) to bone outcomes and fracture risko Preclinical interventions (pharmacotherapies, lifestyle approaches, novel bioactive agents) targeting bone fragility and repair in metabolic contextso Evaluation of metabolic drugs (e.g., SGLT2 inhibitors) for bone health and their potential repurposingo Identification and validation of biomarkers for metabolism-bone crosstalk and fracture risk stratificationo Development of integrated clinical approaches for metabolic and skeletal health managementAppendix: We welcome original research, reviews, and brief communications from endocrinologists, bone biologists, and translational investigators. Topic editors: Faming Tian, Ying Zhang, Ye Liu Source: https://www.frontiersin.org/research-topics/77786/glucose-lipid-metabolic-dysfunction-and-skeletal-fragility-bone-quality-repair-biology-and-targeted-endocrinemetabolic-interventions